United States: FTC Workshop Signals Continued Focus on Prescription Drug Competition

Last Updated: November 17 2017
Article by C. Scott Lent, Matthew Tabas and Matthew H. Fine

On November 8, 2017, the US Federal Trade Commission (FTC) hosted a workshop entitled "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics" to examine the market and economic factors that impact the price of pharmaceuticals, including generic drug competition and supply chain dynamics. The FTC has been particularly aggressive in the prescription drug space in recent years, challenging both mergers that the FTC alleged would substantially lessen competition by eliminating existing and future competition between drug manufacturers, as well as conduct by branded drug manufacturers that the FTC asserts restricts the ability of generic drug manufacturers to compete.1 In addition to these antitrust investigations and enforcement actions, the FTC also develops policy by hosting workshops and requesting public comments, and often uses these opportunities to bring together scholars and practitioners to discuss issues important to its mission of protecting consumers. This workshop signals that parties should expect the FTC to remain active in the pharmaceutical industry during the Trump Administration. However, the FTC may emphasize other methods, such as policy statements or reports, to address what it views as a need both to encourage additional generic drug competition and to reduce the price of pharmaceuticals to consumers generally.


In announcing the workshop, Acting FTC Chairman Maureen K. Ohlhausen noted that "[c]ompetition is key to containing prescription drug costs" and that "it's critical we identify barriers that may prevent drugs from entering the market, even after applicable patent protections have expired." 2 To accomplish this goal, the workshop included speeches from Acting Chairman Ohlhausen and US Food and Drug Commissioner Dr. Scott Gottlieb, as well as panels featuring academics, economists, and industry representatives on generic drug entry and competition, including a discussion of ways to encourage entry and expand access to drugs, as well as panels on the role of intermediaries in the pharmaceutical supply chain (one on pharmacy benefit managers (PBMs) and one on group purchasing organizations (GPOs)).

The FTC's stated purpose for its workshop was to study the barriers to generic drug competition and whether other market forces create inefficiencies that lead to higher drug prices. Acting Chairman Ohlhausen opened the workshop by stating that the Hatch-Waxman Act was enacted to support the broad policy goal of protecting pharmaceutical manufacturers' patent rights in new medicines, which are critical to drive innovation, but also to create legislative incentives to encourage generic drug entry for post-patent pharmaceuticals. This generic drug entry, Acting Chairman Ohlhausen said, causes initial reductions in pharmaceutical prices by twenty to thirty percent and more as additional generic drugs enter the market. The FTC hoped to use the workshop to explore why some markets do not see the same level of generic drug competition when patent protection expires.

Commissioner Gottlieb built on Acting Chairman Ohlhausen's themes and expressed concern about the high costs of life saving medical treatments. He discussed the ways in which the Food and Drug Administration (FDA) has taken steps to encourage generic drug entry, including by expediting the review of the first three generic drug applications where the FDA views competition to be limited, posting a list of off-patent, off-exclusivity products with no approved generic drug offering, hosting its own public meetings to discuss generic drug entry, as well as shortening and streamlining the process for reviewing generic drug applications to reduce review times. Commissioner Gottlieb also expressed concern about what he referred to as the attempts of some "branded firms [to] "game" the system: taking advantage of certain rules, or exploiting loopholes in our system, to delay generic approval" or entering into "restrictive agreements with pharmaceutical supply chain intermediaries[.]"

Fostering Generic Drug Entry

Panelists discussed the benefits of generic drug competition, but identified several dynamics associated with generic drug entry:

  • Patient & Physician Resistance: Many physicians and patients are still resistant to using generic drugs. Panelists attributed this resistance to skepticism regarding the efficacy of generic drugs as well as to promotional efforts by branded manufacturers to encourage use of the branded drug over generics.
  • Unavailability: There may be instances where a generic drug is unavailable in a given market. In some cases, panelists said that a niche patient population may not create enough demand to incentivize generic manufacturers to enter the market. Other challenges that limit the availability of generic drugs could be complex manufacturing processes or shortages of active pharmaceutical ingredients.
  • Consolidation: Panelists also suggested that consolidation among purchasers of generic drugs (i.e., PBMs, wholesalers/distributors, and GPOs) deflates the price of certain generic drugs and has encouraged generic drug manufacturers to exit unprofitable markets. This deflationary pressure allegedly has caused a reduction in generic drug investment and also pushed more manufacturing off shore, which can create vulnerability to supply shortages, quality issues, and the uncertainty of foreign economic policies.
  • Potentially Anticompetitive Conduct: Panelists discussed the steps some branded drug manufacturers allegedly take to limit generic competition, such as: purportedly using allegedly weak or minor patents (such as those related to method of use or release times) to delay generic drug entry; entering into so-called reverse-payment patent settlements, in which value provided by a branded drug manufacturer to the potential generic entrant in the settlement is alleged to have been in exchange for the generic drug manufacturer's agreement to a generic entry date later than would otherwise have occurred; engaging in so-called product hopping, where changes made to an existing product by a branded drug manufacturer are alleged to be for the purpose of transferring patient and prescriber loyalty to a patented product before a generic version of the older product can enter and compete; using the citizen petition process supposedly to delay generic entry rather than raise legitimate safety concern; restricting distribution of the branded drug, e.g., in the case of REMS-restricted drugs, allegedly to deny samples to generic drug manufacturers who may need those samples for bioequivalence testing; and bundling products or offering rebates that violate rules against unlawful exclusive dealing.

Each panelist offered suggestions for how to encourage generic drug entry, but one common theme was to increase antitrust scrutiny to protect against both potentially anticompetitive conduct and market consolidation. Several panelists voiced support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which would require branded drug manufacturers to share samples of drugs needed for generic drug manufacturers' bioequivalence testing.

The Role of Intermediaries

The next two panels each focused on the role of intermediaries (i.e., PBMs, distributors/wholesalers, and GPOs) in the pharmaceutical supply chain in an attempt to understand the role of those entities and their impact on the price of pharmaceuticals generally. Each panel emphasized the complexity of the pharmaceutical supply chain, and in some cases, panelists stated that complexity may allow supply chain participants to extract profits that cause an increase in the price of pharmaceuticals to consumers.


The debate over PBMs focused on two main issues: the impact of rebates to PBMs from drug manufacturers on drug prices and the role PBMs play in pharmacy competition. First, as is at issue in several ongoing lawsuits related to diabetes drugs, the panelists considered whether and how the rebates negotiated between drug manufacturers and PBMs affect the prices paid by ultimate consumers and payors.3 Some panelists argued that a drive for larger rebates pushes up the list price of drugs and that the rebates paid to PBMs add unnecessary costs to the supply chain at the expense of the consumers. Second, a community pharmacist representative suggested that PBMs use their size to take advantage of the complex supply chain and use that supply chain to compete unfairly with independent pharmacists. In response to both of these arguments, a representative of PBMs maintained that PBMs compete fairly, that the complexity of the pharmaceutical supply chain requires the PBM services, which are demanded by their customers, and that rebates have no impact on the prices of pharmaceuticals.


The third panel focused on the role of GPOs and discussed the impact of GPOs' compensation structure (in which they are paid by suppliers, rather than members) on the price and quantities available of the products they purchase. GPOs, which leverage purchasing volume to extract lower prices for healthcare products, are often compensated by their suppliers under a commission model, rather than by their members. Panelists contrasted that model with that of distributors/wholesalers, which offer logistical services to drug manufacturers and are compensated on a service fee basis by the manufacturers themselves. Given that distinction, panelists discussed whether the GPO-pricing model has the effect of increasing prices and lowering volumes as GPOs could benefit from higher than competitive pricing. The panel also discussed whether there are alternative models, such as direct buying programs, that could lead to a more efficient distribution system.

Next Steps

The FTC workshop, as intended, raised more questions than it answered, and signaled an ongoing interest in drug competition by both the FTC and FDA. This process will continue as the FTC further studies drug competition and the complex pharmaceutical supply chain, including by accepting public comments on questions related to the topics discussed during the workshop until December 8, 2017. 4

Although no new policy initiatives were announced, the focus of the panels and the topics addressed by the participants indicate that the FTC will continue to enforce the antitrust laws actively in the pharmaceutical industry. Branded drug manufacturers should be mindful of the antitrust laws as they near the loss of patent exclusivity as attempts to extend that exclusivity may be met with FTC review. Generic drug manufacturers may also see increased attention from antitrust authorities who want to ensure there is adequate competition for post-patent drugs.

Notably, the focus on the role of intermediaries in the pharmaceutical supply chain is important for all industry participants and may indicate the likelihood of FTC inquiry into the business dealings of drug manufacturers and both PBMs and GPOs, which have already been the subject of a number of private litigations.


1 See, e.g., In the Matter of Teva Pharmaceutical Industries Ltd. and Allergan PLC, Docket No. C-4589, Complaint (Jul. 27, 2016); See, e.g., FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013); FTC v. Shire ViroPharma Inc., No. 1:17-cv-0013, Complaint for Injunctive and Other Equitable Relief (D. Del. Feb. 7, 2017).

2 Press Release, US Federal Trade Commission, FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets (Oct. 3, 2017).

3 See, e.g., In re Insulin Pricing Litigation, No. 3:17-cv-00699, Complaint (D.N.J. Feb. 2, 2017).

4 Those questions can be found on the FTC website.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions